DGAP-News: Neovacs S.A.: 2015 Financial Calendar


DGAP-News: Neovacs S.A. / Key word(s): Miscellaneous
Neovacs S.A.: 2015 Financial Calendar

26.01.2015 / 18:30

---------------------------------------------------------------------

PRESS RELEASE

2015 Financial Calendar

 
Paris,  January 26, 2015 - NEOVACS (Alternext Paris : ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases, annonced
today its financial reporting calendar for 2015.

Financial publications will be released prior to the opening of the Paris
stock exchange. This calendar is indicative and subject to change.

  - 2014 Full-Year results:    February 27, 2015

  - Shareholders' AGM:             April 8, 2015

  - 2015 Half-Year results:    September 4, 2015


About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus. Neovacs is also conducting
preclinical development works on other therapeutic vaccines in the fields
of auto-immune diseases, oncology and allergies. The goal of the Kinoid
approach is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr


Contacts 
      

Neovacs
Nathalie Trépo       
+33 (0)1 53 10 93 00   
ntrepo@neovacs.com  

Investor Relations - Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-210228-30
raimund.gabriel@mc-services.eu

Press - U.S. Inquiries - The Ruth Group
Melanie Sollid-Penton
1.646.536.7023           
msollid@theruthgroup.com



---------------------------------------------------------------------

26.01.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                             
Company:     Neovacs S.A.                                        
             3-5, Impasse Reille                                 
             75014 Paris                                         
             France                                              
Phone:       +33 (0)1 53 10 93 00                                
Fax:         +33 (0)1 53 10 93 03                                
E-mail:      www.neovacs.fr                                      
Internet:    info@neovacs.fr                                     
ISIN:        FR0004032746                                        
WKN:         A1CVKR                                              
Listed:      Freiverkehr in Stuttgart; Frankfurt in Open Market  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
316457 26.01.2015